摘要:目的:了解2007~2008年成都地區(qū)17家醫(yī)院生物制品及生化藥品的使用狀況。方法:采用限定日劑量(DDD)的方法,對成都地區(qū)2007~2008年17家醫(yī)院生物制品及生化藥品的銷售金額、用藥頻度(DDDs)等進行統(tǒng)計分析。結(jié)果:2007年、2008年成都地區(qū)17家醫(yī)院生物制品及生化藥品銷售總額分別為7338萬元、9786萬元;分別占總銷售額的4.83%、5.00%。銷售金額進入總銷售額排名前100位的生物制品及生化藥品有:人血白蛋白、胸腺肽、丙種球蛋白、促白細胞生長素和環(huán)磷腺苷。環(huán)磷腺苷在生物制品及生化藥品中的DDDs最高。結(jié)論:生物制品及生化藥品的價格及供給對其臨床使用有較大的限制。
Abstract: Objective: To evaluate the current situation and the trend of biological products and biochemical drugs used in Chengdu city in 2007 to 2008. Methods: Consumption of biological products and biochemical drugs used in 17 hospitals of Chengdu city in 2007 to 2008 were analyzed by the way of sum DDD and DDDs ranking. Results: The total cost of the biological products and biochemical drugs used in Chengdu city in was 73.38 and 97.86 million yuan in 2007 to 2008, it accounted for 4.83% and 5.00% of the total cost. Human serum albumin, thymosin, gamma globulin, interleukin promoting growth hormone and adenosine cyclophosphate were the drugs in the first 100 cost list. The DDDs of adenosine cyclophosphate was highest among biological products and biochemical drugs. Conclusion: The cost and supply of biological products and biochemical drugs were great limitations of their clinical application.

引用本文： 吳斌,柳汝明,唐堯. 2007~2008年成都地區(qū)17家醫(yī)院生物制品及生化藥品利用狀況分析. 華西醫(yī)學, 2009, 24(11): 2969-2971. doi: 復(fù)制

版權(quán)信息： ?四川大學華西醫(yī)院華西期刊社《華西醫(yī)學》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編